Livanova PLC Form 4 insider transactions

LivaNova PLC Director William A. Kozy reported the settlement of vested restricted stock units, the sale of shares to cover tax liabilities, and the grant of new restricted stock units, as detailed in a recent SEC Form 4 filing.

LivaNova PLC Director Barry James Christopher reported the vesting of 3,416 restricted stock units, the sale of 410 shares for tax purposes, and the grant of 4,042 new restricted stock units.

LivaNova PLC Director Brooke Story filed a Form 4 detailing the vesting of restricted stock units, a tax-related share disposition, and the grant of new equity awards.

LivaNova PLC Director Stacy Enxing Seng reported the vesting of restricted stock units, the acquisition of ordinary shares, and the disposition of shares for tax purposes, alongside a new grant of restricted stock units.

LivaNova PLC Director Peter M. Wilver reported the vesting of 3,416 restricted stock units, the acquisition of an equivalent number of ordinary shares, and a new grant of 4,042 restricted stock units, alongside the withholding of 410 shares for tax purposes.

LivaNova PLC's Chief Innovation Officer, Ahmet Tezel, reported the vesting of 2,967 restricted stock units and the subsequent sale of 1,032 shares to cover tax obligations, resulting in a net increase of 1,935 beneficially owned ordinary shares.

LivaNova PLC Director Susan M. Podlogar has been granted 4,042 Restricted Stock Units (RSUs) under the company's 2025 Director Incentive Award Plan, vesting on June 15, 2026.

Ahmet Tezel, Chief Innovation Officer of LivaNova PLC, was granted restricted stock units, performance stock units, and stock appreciation rights on March 30, 2025, under the company's 2022 Incentive Award Plan.

Stephanie Bolton, President of Global Epilepsy at LivaNova PLC, reports the vesting and acquisition of restricted stock units (RSUs), performance stock units (PSUs), and stock appreciation rights (SARs) on March 30, 2025.

LivaNova PLC CEO Vladimir Makatsaria reports the acquisition and disposal of ordinary shares and derivative securities, including restricted stock units, performance stock units, and stock appreciation rights, as part of incentive plans.

Director William A. Kozy settled restricted stock units for LivaNova PLC ordinary shares on March 30, 2025, and shares were withheld to cover tax liabilities.

Chief Legal Officer Michael Damon Hutchinson reports acquisition and disposal of LivaNova PLC ordinary shares and derivative securities, including restricted stock units, performance stock units, and stock appreciation rights, as per Section 16(a) filing.

Chief Financial Officer of LivaNova PLC, Alex Shvartsburg, reports the vesting and acquisition of ordinary shares, restricted stock units (RSUs), performance stock units (PSUs), and stock appreciation rights (SARs) on March 30, 2025.

Natalia Kozmina, Chief Human Resources Officer of LivaNova PLC, reports the grant of restricted stock units, performance stock units, and stock appreciation rights on March 30, 2025.

Franco Poletti, President of Cardiopulmonary at LivaNova PLC, reports the acquisition and disposal of ordinary shares and derivative securities, including restricted stock units (RSUs), performance stock units (PSUs), and stock appreciation rights (SARs).

LivaNova's Chief Legal Officer, Michael Damon Hutchinson, acquired shares through vested restricted stock units and sold shares to cover tax obligations.

LivaNova's President of Cardiopulmonary, Franco Poletti, reports the vesting of restricted stock units and subsequent share transactions.

Director James Christopher Barry exercised stock options and sold shares to cover tax liabilities on December 15, 2024.

LivaNova's Chief Financial Officer, Alex Shvartsburg, acquired 613 ordinary shares through the vesting of restricted stock units and disposed of 229 shares to cover tax obligations.

Director Susan M Podlogar was granted 2,355 restricted stock units (RSUs) of LivaNova PLC, which will vest on December 15, 2025.

Director Francesco Bianchi sold 1,250 ordinary shares of LivaNova PLC at a price of $50.99 per share on December 11, 2024.

Franco Poletti, President of Cardiopulmonary at LivaNova PLC, received grants of restricted stock units, performance stock units, and stock appreciation rights on September 15, 2024.

Director Francesco Bianchi sold 1,500 ordinary shares of LivaNova PLC on September 11, 2024, at a price of $46.58 per share.

Director James Christopher Barry acquired 3,416 Restricted Stock Units (RSUs) of LivaNova PLC on June 15, 2024, which will vest on June 15, 2025.

Director Peter M. Wilver reports acquisition and disposal of LivaNova PLC ordinary shares and restricted stock units.

Ahmet Tezel, Chief Innovation Officer of LivaNova PLC, reports the acquisition of restricted stock units, performance stock units, and stock appreciation rights.

Director Enxing Seng Stacy reports acquisition and disposal of LivaNova PLC ordinary shares related to restricted stock units.

CFO Alex Shvartsburg reports the settlement of Restricted Stock Units (RSUs) and shares withheld for tax liability.

Director Francesco Bianchi reports acquisition and disposal of LivaNova PLC ordinary shares and restricted stock units.

Director Todd C. Schermerhorn reports acquisition and disposal of LivaNova PLC ordinary shares and restricted stock units.